1
|
Ripa L, Sandmark J, Hughes G, Shamovsky I, Gunnarsson A, Johansson J, Llinas A, Collins M, Jung B, Novén A, Pemberton N, Mogemark M, Xiong Y, Li Q, Tångefjord S, Ek M, Åstrand A. Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism. J Med Chem 2023; 66:14188-14207. [PMID: 37797307 DOI: 10.1021/acs.jmedchem.3c01269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/07/2023]
Abstract
Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family mainly targeting cytosolic nonhistone substrates, such as α-tubulin, cortactin, and heat shock protein 90 to regulate cell proliferation, metastasis, invasion, and mitosis in tumors. We describe the identification and characterization of a series of 2-(difluoromethyl)-1,3,4-oxadiazoles (DFMOs) as selective nonhydroxamic acid HDAC6 inhibitors. By comparing structure-activity relationships and performing quantum mechanical calculations of the HDAC6 catalytic mechanism, we show that potent oxadiazoles are electrophilic substrates of HDAC6 and propose a mechanism for the bioactivation. We also observe that the inherent electrophilicity of the oxadiazoles makes them prone to degradation in water solution and the generation of potentially toxic products cannot be ruled out, limiting the developability for chronic diseases. However, the oxadiazoles demonstrate high oral bioavailability and low in vivo clearance and are excellent tools for studying the role of HDAC6 in vitro and in vivo in rats and mice.
Collapse
Affiliation(s)
- Lena Ripa
- Respiratory & Immunology (R&I), Research and Early Development, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
| | - Jenny Sandmark
- Discovery Sciences, Research and Early Development, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
| | - Glyn Hughes
- Respiratory & Immunology (R&I), Research and Early Development, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
| | - Igor Shamovsky
- Respiratory & Immunology (R&I), Research and Early Development, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
| | - Anders Gunnarsson
- Discovery Sciences, Research and Early Development, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
| | - Julia Johansson
- Clinical Pharmacology and Safety Sciences, Research and Early Development, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
| | - Antonio Llinas
- Respiratory & Immunology (R&I), Research and Early Development, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
| | - Mia Collins
- Respiratory & Immunology (R&I), Research and Early Development, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
| | - Bomi Jung
- Discovery Sciences, Research and Early Development, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
| | - Anna Novén
- Discovery Sciences, Research and Early Development, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
| | - Nils Pemberton
- Respiratory & Immunology (R&I), Research and Early Development, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
| | - Mickael Mogemark
- Clinical Pharmacology and Safety Sciences, Research and Early Development, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
| | - Yao Xiong
- Pharmaron Beijing, Co. Ltd., No. 6, Taihe Road, BDA, Beijing 100176, China
| | - Qing Li
- Pharmaron Beijing, Co. Ltd., No. 6, Taihe Road, BDA, Beijing 100176, China
| | - Stefan Tångefjord
- Discovery Sciences, Research and Early Development, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
| | - Margareta Ek
- Discovery Sciences, Research and Early Development, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
| | - Annika Åstrand
- Respiratory & Immunology (R&I), Research and Early Development, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
| |
Collapse
|
2
|
Ek M, Hansen LP, Chen FR, van Dyck D, Kisielowski C, Specht P, Damsgaard CD, Jinschek JR, Helveg S. Probing Catalyst Surfaces at the Atomic-scale. Microsc Microanal 2023; 29:1291. [PMID: 37613447 DOI: 10.1093/micmic/ozad067.660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/25/2023]
Affiliation(s)
- M Ek
- Topsoe A/S, Kgs. Lyngby, Denmark
- Centre for Analysis and Synthesis & NanoLund, Lund University, Lund, Sweden
| | | | - F R Chen
- Department of Materials Science and Engineering, City University of Hong Kong, Kowlook, Hong Kong
| | - D van Dyck
- Departments of Physics, EMAT, University of Antwerp, Antwerp, Belgium
| | - C Kisielowski
- Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley CA, United States
| | - P Specht
- Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley CA, United States
| | - C D Damsgaard
- National Center for Nano Fabrication and Characterization, Technical University of Denmark, Kgs. Lyngby, Denmark
- Center for Visualizing Catalytic Processes (VISION), Department of Physics, Technical University of Denmark, Kgs. Lyngby, Denmark
| | - J R Jinschek
- National Center for Nano Fabrication and Characterization, Technical University of Denmark, Kgs. Lyngby, Denmark
- Center for Visualizing Catalytic Processes (VISION), Department of Physics, Technical University of Denmark, Kgs. Lyngby, Denmark
| | - S Helveg
- Center for Visualizing Catalytic Processes (VISION), Department of Physics, Technical University of Denmark, Kgs. Lyngby, Denmark
| |
Collapse
|
3
|
O’Mahony G, Petersen J, Ek M, Rae R, Johansson C, Jianming L, Prokoph N, Bergström F, Bamberg K, Giordanetto F, Zarrouki B, Karlsson D, Hogner A. Discovery by Virtual Screening of an Inhibitor of CDK5-Mediated PPARγ Phosphorylation. ACS Med Chem Lett 2022; 13:681-686. [PMID: 35450368 PMCID: PMC9014497 DOI: 10.1021/acsmedchemlett.1c00715] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 03/08/2022] [Indexed: 12/18/2022] Open
Abstract
Thiazolidinedione PPARγ agonists such as rosiglitazone and pioglitazone are effective antidiabetic drugs, but side effects have limited their use. It has been posited that their positive antidiabetic effects are mainly mediated by the inhibition of the CDK5-mediated Ser273 phosphorylation of PPARγ, whereas the side effects are linked to classical PPARγ agonism. Thus compounds that inhibit PPARγ Ser273 phosphorylation but lack classical PPARγ agonism have been sought as safer antidiabetic therapies. Herein we report the discovery by virtual screening of 10, which is a potent PPARγ binder and in vitro inhibitor of the CDK5-mediated phosphorylation of PPARγ Ser273 and displays negligible PPARγ agonism in a reporter gene assay. The pharmacokinetic properties of 10 are compatible with oral dosing, enabling preclinical in vivo testing, and a 7 day treatment demonstrated an improvement in insulin sensitivity in the ob/ob diabetic mouse model.
Collapse
Affiliation(s)
- Gavin O’Mahony
- Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43183, Sweden
| | - Jens Petersen
- Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden
| | - Margareta Ek
- Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden
| | - Rebecca Rae
- Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden
| | - Carina Johansson
- Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden
| | - Liu Jianming
- Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden
| | - Nina Prokoph
- Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden
| | - Fredrik Bergström
- DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43183, Sweden
| | - Krister Bamberg
- Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43183, Sweden
| | - Fabrizio Giordanetto
- Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43183, Sweden
| | - Bader Zarrouki
- Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43183, Sweden
| | - Daniel Karlsson
- Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43183, Sweden
| | - Anders Hogner
- Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43183, Sweden
| |
Collapse
|
4
|
Price NPJ, Jackson MA, Hartman TM, Brändén G, Ek M, Koch AA, Kennedy PD. Branched Chain Lipid Metabolism As a Determinant of the N-Acyl Variation of Streptomyces Natural Products. ACS Chem Biol 2021; 16:116-124. [PMID: 33411499 DOI: 10.1021/acschembio.0c00799] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Branched-chain fatty acids (BCFA) are encountered in Gram-positive bacteria, but less so in other organisms. The bacterial BCFA in membranes are typically saturated, with both odd- and even-numbered carbon chain lengths, and with methyl branches at either the ω-1 (iso) or ω-2 (anteiso) positions. The acylation with BCFA also contributes to the structural diversity of microbial natural products and potentially modulates biological activity. For the tunicamycin (TUN) family of natural products, the toxicity toward eukaryotes is highly dependent upon N-acylation with trans-2,3-unsaturated BCFA. The loss of the 2,3-unsaturation gives modified TUN with reduced eukaryotic toxicity but crucially with retention of the synergistic enhancement of the β-lactam group of antibiotics. Here, we infer from genomics, mass spectrometry, and deuterium labeling that the trans-2,3-unsaturated TUN variants and the saturated cellular lipids found in TUN-producing Streptomyces are derived from the same pool of BCFA metabolites. Moreover, non-natural primers of BCFA metabolism are selectively incorporated into the cellular lipids of TUN-producing Streptomyces and concomitantly produce structurally novel neo-branched TUN N-acyl variants.
Collapse
Affiliation(s)
- Neil P. J. Price
- USDA, Agricultural Research Service, National Center for Agricultural Utilization Research, 1815 N. University St., Peoria, Illinois 61604, United States
| | - Michael A. Jackson
- USDA, Agricultural Research Service, National Center for Agricultural Utilization Research, 1815 N. University St., Peoria, Illinois 61604, United States
| | - Trina M. Hartman
- USDA, Agricultural Research Service, National Center for Agricultural Utilization Research, 1815 N. University St., Peoria, Illinois 61604, United States
| | - Gisela Brändén
- Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden
| | - Margareta Ek
- Structure, Biophysics & FBLG, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden
| | - Aaron A. Koch
- Cayman Chemical, 1180 E. Ellsworth Rd., Ann Arbor, Michigan 48108, United States
| | - Paul D. Kennedy
- Cayman Chemical, 1180 E. Ellsworth Rd., Ann Arbor, Michigan 48108, United States
| |
Collapse
|
5
|
Hering J, Dunevall E, Snijder A, Eriksson PO, Jackson MA, Hartman TM, Ting R, Chen H, Price NPJ, Brändén G, Ek M. Exploring the Active Site of the Antibacterial Target MraY by Modified Tunicamycins. ACS Chem Biol 2020; 15:2885-2895. [PMID: 33164499 DOI: 10.1021/acschembio.0c00423] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The alarming growth of antibiotic resistance that is currently ongoing is a serious threat to human health. One of the most promising novel antibiotic targets is MraY (phospho-MurNAc-pentapeptide-transferase), an essential enzyme in bacterial cell wall synthesis. Through recent advances in biochemical research, there is now structural information available for MraY, and for its human homologue GPT (GlcNAc-1-P-transferase), that opens up exciting possibilities for structure-based drug design. The antibiotic compound tunicamycin is a natural product inhibitor of MraY that is also toxic to eukaryotes through its binding to GPT. In this work, we have used tunicamycin and modified versions of tunicamycin as tool compounds to explore the active site of MraY and to gain further insight into what determines inhibitor potency. We have investigated tunicamycin variants where the following motifs have been modified: the length and branching of the tunicamycin fatty acyl chain, the saturation of the fatty acyl chain, the 6″-hydroxyl group of the GlcNAc ring, and the ring structure of the uracil motif. The compounds are analyzed in terms of how potently they bind to MraY, inhibit the activity of the enzyme, and affect the protein thermal stability. Finally, we rationalize these results in the context of the protein structures of MraY and GPT.
Collapse
Affiliation(s)
- Jenny Hering
- Structure, Biophysics and FBLG, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden
- Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden
| | - Elin Dunevall
- Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden
| | - Arjan Snijder
- Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden
| | - Per-Olof Eriksson
- Structure, Biophysics and FBLG, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden
| | - Michael A. Jackson
- U.S. Department of Agriculture, National Center for Agricultural Utilization Research, Peoria, Illinois 61604, United States
| | - Trina M. Hartman
- U.S. Department of Agriculture, National Center for Agricultural Utilization Research, Peoria, Illinois 61604, United States
| | - Ran Ting
- Chemistry and Chemical Biology Centre, Bioland Laboratory, Guangzhou, China
| | - Hongming Chen
- Chemistry and Chemical Biology Centre, Bioland Laboratory, Guangzhou, China
| | - Neil P. J. Price
- U.S. Department of Agriculture, National Center for Agricultural Utilization Research, Peoria, Illinois 61604, United States
| | - Gisela Brändén
- Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden
| | - Margareta Ek
- Structure, Biophysics and FBLG, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden
| |
Collapse
|
6
|
Brunes M, Altman D, Pålsson M, Söderberg MW, Ek M. Impact of hysterectomy on analgesic, psychoactive and neuroactive drug use in women with endometriosis: nationwide cohort study. BJOG 2020; 128:846-855. [PMID: 32804432 PMCID: PMC7984057 DOI: 10.1111/1471-0528.16469] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/10/2020] [Indexed: 12/17/2022]
Abstract
Objective To evaluate how hysterectomy affects the prescription of analgesic, psychotropic and neuroactive drugs in women with endometriosis using population‐based nationwide registers. Design Nationwide cohort study. Setting Swedish national registers, from 1 January 2009 to 31 December 2018. Population Women with benign disease undergoing a total hysterectomy during the 4‐year period of 2012–2015. Women with endometriosis (n = 1074) were identified and compared with women who did not have endometriosis (n = 10 890). Methods Prospectively collected data from two population‐based registers were linked: the Swedish National Quality Register of Gynaecological Surgery and the Swedish National Drug Register. Multivariate logistic regression was used as the main statistical method. Main outcome measures Changes in drug prescription over time for 3 years prior to and 3 years after hysterectomy. Results The frequency of prescription of analgesics was higher in women with endometriosis compared with women without endometriosis (OR 2.2, 95% CI 1.7–2.9). Among women with endometriosis, the prescription of analgesics (OR 1.0, 95% CI 0.8–1.2) did not decrease 3 years after hysterectomy compared with the 3 years prior to surgery. There was also a significantly higher rate of prescription of psychoactive (OR 1.6, 95% CI 1.4–2.0) and neuroactive drugs (OR 1.9, 95% CI 1.3–2.7) in the long term postoperatively. Conclusions In women undergoing hysterectomy, endometriosis was associated with a higher prescription rate of analgesics. In the endometriosis group the prescription of analgesic, psychoactive and neuroactive drugs did not decrease when comparing prescription rates for the 3 years prior to and the 3 years after surgery. Tweetable abstract In women with endometriosis, the long‐term prescription of analgesics did not decrease after hysterectomy. In women with endometriosis, the long‐term prescription of analgesics did not decrease after hysterectomy.
Collapse
Affiliation(s)
- M Brunes
- Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden.,Division of Obstetrics and Gynaecology, Södersjukhuset, Stockholm, Sweden
| | - D Altman
- Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.,Stockholm Urogynaecological Clinic, Stockholm, Sweden
| | - M Pålsson
- Department of Obstetrics and Gynaecology, Institute of Clinical Sciences, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden
| | - M W Söderberg
- Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden.,Division of Obstetrics and Gynaecology, Södersjukhuset, Stockholm, Sweden
| | - M Ek
- Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden.,Division of Obstetrics and Gynaecology, Södersjukhuset, Stockholm, Sweden
| |
Collapse
|
7
|
Ek M, Lehmann S, Wallenberg R. Electron channelling: challenges and opportunities for compositional analysis of nanowires by TEM. Nanotechnology 2020; 31:364005. [PMID: 32454471 DOI: 10.1088/1361-6528/ab9679] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Energy dispersive x-ray spectroscopy in a transmission electron microscope is often the first method employed to characterize the composition of nanowires. Ideally, it should be accurate and sensitive down to fractions of an atomic percent, and quantification results are often reported as such. However, one can often get substantial errors in accuracy even though the precision is high: for nanowires it is common for the quantified V/III atomic ratios to differ noticeably from 1. Here we analyse the origin of this systematic error in accuracy for quantification of the composition of III-V nanowires. By varying the electron illumination direction, we find electron channelling to be the primary cause, being responsible for errors in quantified V/III atomic ratio of 50%. Knowing the source of the systematic errors is required for applying appropriate corrections. Lastly, we show how channelling effects can provide information on the crystallographic position of dopants.
Collapse
Affiliation(s)
- M Ek
- Centre for Analysis and Synthesis, Lund University, Box 124, Lund 22100, Sweden. NanoLund, Lund University, Box 118, Lund 22100, Sweden
| | | | | |
Collapse
|
8
|
Munck Af Rosenschöld M, Johannesson P, Nikitidis A, Tyrchan C, Chang HF, Rönn R, Chapman D, Ullah V, Nikitidis G, Glader P, Käck H, Bonn B, Wågberg F, Björkstrand E, Andersson U, Swedin L, Rohman M, Andreasson T, Bergström EL, Jiang F, Zhou XH, Lundqvist AJ, Malmberg A, Ek M, Gordon E, Pettersen A, Ripa L, Davis AM. Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1 S,2 S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma. J Med Chem 2019; 62:7769-7787. [PMID: 31415176 DOI: 10.1021/acs.jmedchem.9b00555] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
While bronchodilators and inhaled corticosteroids are the mainstay of asthma treatment, up to 50% of asthmatics remain uncontrolled. Many studies show that the cysteinyl leukotriene cascade remains highly activated in some asthmatics, even those on high-dose inhaled or oral corticosteroids. Hence, inhibition of the leukotriene C4 synthase (LTC4S) enzyme could provide a new and differentiated core treatment for patients with a highly activated cysteinyl leukotriene cascade. Starting from a screening hit (3), a program to discover oral inhibitors of LTC4S led to (1S,2S)-2-({5-[(5-chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid (AZD9898) (36), a picomolar LTC4S inhibitor (IC50 = 0.28 nM) with high lipophilic ligand efficiency (LLE = 8.5), which displays nanomolar potency in cells (peripheral blood mononuclear cell, IC50,free = 6.2 nM) and good in vivo pharmacodynamics in a calcium ionophore-stimulated rat model after oral dosing (in vivo, IC50,free = 34 nM). Compound 36 mitigates the GABA binding, hepatic toxicity signal, and in vivo toxicology findings of an early lead compound 7 with a human dose predicted to be 30 mg once daily.
Collapse
Affiliation(s)
| | | | | | | | | | - Robert Rönn
- Orexo AB , Virdings allé 32A , SE-75450 Uppsala , Sweden
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Baresel C, Ek M, Ejhed H, Allard AS, Magnér J, Dahlgren L, Westling K, Wahlberg C, Fortkamp U, Söhr S, Harding M, Fång J, Karlsson J. Sustainable treatment systems for removal of pharmaceutical residues and other priority persistent substances. Water Sci Technol 2019; 79:537-543. [PMID: 30924808 DOI: 10.2166/wst.2019.080] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Pharmaceutical residues and other emerging substances commonly summarised as micropollutants pass through wastewater treatment plants (WWTPs) and end up in the receiving waters and sludge. Many studies have investigated the removal efficiency of various techniques but a holistic evaluation of various relevant treatment alternatives regarding both the removal efficiency for various micropollutants, investment and operating costs, environmental impacts and future comprehensiveness is still lacking. This paper provides the results from a large 3-year project about the evaluation of sustainable treatment systems for removal of various micropollutants or disruptive effects at Swedish WWTPs and their environmental, economic and future sustainability. The presented results are based on our own pilot tests and related assessment and modelling efforts and provide a holistic view on advanced treatment of wastewater for removal of micropollutants.
Collapse
Affiliation(s)
- C Baresel
- IVL Swedish Environmental Research Institute, Stockholm, Sweden E-mail:
| | - M Ek
- IVL Swedish Environmental Research Institute, Stockholm, Sweden E-mail:
| | - H Ejhed
- IVL Swedish Environmental Research Institute, Stockholm, Sweden E-mail:
| | - A-S Allard
- IVL Swedish Environmental Research Institute, Stockholm, Sweden E-mail:
| | - J Magnér
- IVL Swedish Environmental Research Institute, Stockholm, Sweden E-mail:
| | - L Dahlgren
- IVL Swedish Environmental Research Institute, Stockholm, Sweden E-mail:
| | - K Westling
- IVL Swedish Environmental Research Institute, Stockholm, Sweden E-mail:
| | - C Wahlberg
- Stockholm Vatten och Avfall, Stockholm, Sweden
| | - U Fortkamp
- IVL Swedish Environmental Research Institute, Stockholm, Sweden E-mail:
| | - S Söhr
- Sydvästra Stockholmsregionens VA-verksaktiebolag - SYVAB, Grödinge, Sweden
| | - M Harding
- IVL Swedish Environmental Research Institute, Stockholm, Sweden E-mail:
| | - J Fång
- IVL Swedish Environmental Research Institute, Stockholm, Sweden E-mail:
| | - J Karlsson
- IVL Swedish Environmental Research Institute, Stockholm, Sweden E-mail:
| |
Collapse
|
10
|
Hering J, Dunevall E, Ek M, Brändén G. Structural basis for selective inhibition of antibacterial target MraY, a membrane-bound enzyme involved in peptidoglycan synthesis. Drug Discov Today 2018; 23:1426-1435. [DOI: 10.1016/j.drudis.2018.05.020] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2017] [Revised: 04/13/2018] [Accepted: 05/14/2018] [Indexed: 12/16/2022]
|
11
|
Ek M, Beinik I, Bruix A, Wendt S, Lauritsen JV, Helveg S. Step edge structures on the anatase TiO2 (001) surface studied by atomic-resolution TEM and STM. Faraday Discuss 2018; 208:325-338. [DOI: 10.1039/c7fd00222j] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Atomic arrangements in oxide surfaces can be uncovered by combining side view imaging using transmission electron microscopy and top view imaging using scanning tunnelling microscopy.
Collapse
Affiliation(s)
- M. Ek
- Haldor Topsoe A/S
- DK-2800 Kgs. Lyngby
- Denmark
| | - I. Beinik
- Interdisciplinary Nanoscience Center (iNANO)
- Department of Physics and Astronomy
- Aarhus University
- DK-800 Aarhus C
- Denmark
| | - A. Bruix
- Interdisciplinary Nanoscience Center (iNANO)
- Department of Physics and Astronomy
- Aarhus University
- DK-800 Aarhus C
- Denmark
| | - S. Wendt
- Interdisciplinary Nanoscience Center (iNANO)
- Department of Physics and Astronomy
- Aarhus University
- DK-800 Aarhus C
- Denmark
| | - J. V. Lauritsen
- Interdisciplinary Nanoscience Center (iNANO)
- Department of Physics and Astronomy
- Aarhus University
- DK-800 Aarhus C
- Denmark
| | - S. Helveg
- Haldor Topsoe A/S
- DK-2800 Kgs. Lyngby
- Denmark
| |
Collapse
|
12
|
Moliner C, Badia JD, Bosio B, Arato E, Kittikorn T, Strömberg E, Teruel-Juanes R, Ek M, Karlsson S, Ribes-Greus A. Thermal and thermo-oxidative stability and kinetics of decomposition of PHBV/sisal composites. CHEM ENG COMMUN 2017. [DOI: 10.1080/00986445.2017.1384921] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- C. Moliner
- Dipartimento di Ingegneria Civile, Chimica e Ambientale (DICCA), Università degli Studi di Genova, Genova, Italy
- Instituto de Tecnología de los Materiales (ITM), Universidad Politècnica de València (UPV), Valencia, Spain
| | - J. D. Badia
- Instituto de Tecnología de los Materiales (ITM), Universidad Politècnica de València (UPV), Valencia, Spain
- Department of Chemical Engineering, School of Engineering, Universitat de València (UV), Burjassot, Spain
| | - B. Bosio
- Dipartimento di Ingegneria Civile, Chimica e Ambientale (DICCA), Università degli Studi di Genova, Genova, Italy
| | - E. Arato
- Dipartimento di Ingegneria Civile, Chimica e Ambientale (DICCA), Università degli Studi di Genova, Genova, Italy
| | - T. Kittikorn
- School of Chemical Science and Engineering, Fibre and Polymer Technology, KTH – Royal Institute of Technology, Stockholm, Sweden
- Department of Materials Science and Technology, Faculty of Science, Prince of Songkla University, Songkhla, Thailand
| | - E. Strömberg
- School of Chemical Science and Engineering, Fibre and Polymer Technology, KTH – Royal Institute of Technology, Stockholm, Sweden
| | - R. Teruel-Juanes
- Instituto de Tecnología de los Materiales (ITM), Universidad Politècnica de València (UPV), Valencia, Spain
| | - M. Ek
- School of Chemical Science and Engineering, Fibre and Polymer Technology, KTH – Royal Institute of Technology, Stockholm, Sweden
| | - S. Karlsson
- School of Chemical Science and Engineering, Fibre and Polymer Technology, KTH – Royal Institute of Technology, Stockholm, Sweden
| | - A. Ribes-Greus
- Instituto de Tecnología de los Materiales (ITM), Universidad Politècnica de València (UPV), Valencia, Spain
| |
Collapse
|
13
|
Badia J, Strömberg E, Kittikorn T, Ek M, Karlsson S, Ribes-Greus A. Relevant factors for the eco-design of polylactide/sisal biocomposites to control biodegradation in soil in an end-of-life scenario. Polym Degrad Stab 2017. [DOI: 10.1016/j.polymdegradstab.2017.06.004] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
14
|
Hakulinen JK, Hering J, Brändén G, Chen H, Snijder A, Ek M, Johansson P. MraY–antibiotic complex reveals details of tunicamycin mode of action. Nat Chem Biol 2017; 13:265-267. [DOI: 10.1038/nchembio.2270] [Citation(s) in RCA: 70] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2016] [Accepted: 11/01/2016] [Indexed: 12/24/2022]
|
15
|
Gil-Castell O, Badia J, Kittikorn T, Strömberg E, Ek M, Karlsson S, Ribes-Greus A. Impact of hydrothermal ageing on the thermal stability, morphology and viscoelastic performance of PLA/sisal biocomposites. Polym Degrad Stab 2016. [DOI: 10.1016/j.polymdegradstab.2016.03.038] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
16
|
Kawatkar SP, Gagnon M, Hoesch V, Tiong-Yip C, Johnson K, Ek M, Nilsson E, Lister T, Olsson L, Patel J, Yu Q. Design and structure-activity relationships of novel inhibitors of human rhinovirus 3C protease. Bioorg Med Chem Lett 2016; 26:3248-3252. [PMID: 27265257 DOI: 10.1016/j.bmcl.2016.05.066] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Revised: 05/19/2016] [Accepted: 05/21/2016] [Indexed: 10/21/2022]
Abstract
Human rhinovirus (HRV) is a primary cause of common cold and is linked to exacerbation of underlying respiratory diseases such as asthma and COPD. HRV 3C protease, which is responsible for cleavage of viral polyprotein in to proteins essential for viral life-cycle, represents an important target. We have designed proline- and azetidine-based analogues of Rupintrivir that target the P2 pocket of the binding site. Potency optimization, aided with X-ray crystallography and quantum mechanical calculations, led to compounds with activity against a broad spectrum of HRV serotypes. Altogether, these compounds represent alternative starting points to identify promising leads in our continual efforts to treat HRV infections.
Collapse
Affiliation(s)
- S P Kawatkar
- AstraZeneca Infection Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, MA, United States.
| | - M Gagnon
- AstraZeneca Infection Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, MA, United States
| | - V Hoesch
- AstraZeneca Infection Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, MA, United States
| | - C Tiong-Yip
- AstraZeneca Infection Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, MA, United States
| | - K Johnson
- AstraZeneca Infection Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, MA, United States
| | - M Ek
- Discovery Sciences, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
| | - E Nilsson
- Discovery Sciences, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
| | - T Lister
- AstraZeneca Infection Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, MA, United States
| | - L Olsson
- Discovery Sciences, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
| | - J Patel
- Discovery Sciences, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, United States
| | - Q Yu
- AstraZeneca Infection Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, MA, United States
| |
Collapse
|
17
|
Barkauskaite V, Ek M, Popovic K, Harris HE, Wahren-Herlenius M, Nyberg F. Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus 2016; 16:794-802. [PMID: 17895302 DOI: 10.1177/0961203307081895] [Citation(s) in RCA: 69] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
HMGB1 is a pro-inflammatory cytokine that together with TNF-α and IL-1β is involved in the pathogenesis of spontaneously occurring skin lesions in lupus erythematosus. The purpose of the present study was to explore the sequence of events in HMGB1, TNF-α and IL-1β expression under development and resolution of experimentally induced CLE lesions. The study involved investigation of 38 serial skin biopsies acquired from photoprovoked skin lesions of nine CLE patients, using immunohistochemical staining of tissue sections. In biopsies from the clinically most active phase of skin involvement extracellular, secreted HMGB1 and increased cytoplasmic HMGB1 were found, as compared with the late and fading lesions or non-lesional skin. Besides HMGB1, increased expression of TNF-α and IL-1β was observed in dermal infiltrates of the induced CLE lesions. These cytokines were however not upregulated in all lesions, and increased expression of IL-1β was seen predominantly in late biopsies. In conclusion, extracellular and cytoplasmic HMGB1 coincides with the clinically most active phase of photoinduced lesions of cutaneous lupus, and suggests that HMGB1 is an important factor in the inflammatory autoimmune process of CLE. HMGB1 can induce expression of TNF-α and IL-1β, and formation of a pro-inflammatory loop between HMGB1, TNF-α, and IL-1β may be responsible for the prolonged and sustained inflammation in CLE. Lupus (2007) 16, 794—802.
Collapse
Affiliation(s)
- V Barkauskaite
- Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
| | | | | | | | | | | |
Collapse
|
18
|
Douthwaite JA, Sridharan S, Huntington C, Hammersley J, Marwood R, Hakulinen JK, Ek M, Sjögren T, Rider D, Privezentzev C, Seaman JC, Cariuk P, Knights V, Young J, Wilkinson T, Sleeman M, Finch DK, Lowe DC, Vaughan TJ. Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1. MAbs 2015; 7:152-66. [PMID: 25484051 PMCID: PMC4622665 DOI: 10.4161/19420862.2014.985158] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs) are desirable for intervention in a wide range of disease processes. The discovery of such antibodies is challenging due to a lack of stability of many GPCRs as purified proteins. We describe here the generation of Fpro0165, a human anti-formyl peptide receptor 1 (FPR1) antibody generated by variable domain engineering of an antibody derived by immunization of transgenic mice expressing human variable region genes. Antibody isolation and subsequent engineering of affinity, potency and species cross-reactivity using phage display were achieved using FPR1 expressed on HEK cells for immunization and selection, along with calcium release cellular assays for antibody screening. Fpro0165 shows full neutralization of formyl peptide-mediated activation of primary human neutrophils. A crystal structure of the Fpro0165 Fab shows a long, protruding VH CDR3 of 24 amino acids and in silico docking with a homology model of FPR1 suggests that this long VH CDR3 is critical to the predicted binding mode of the antibody. Antibody mutation studies identify the apex of the long VH CDR3 as key to mediating the species cross-reactivity profile of the antibody. This study illustrates an approach for antibody discovery and affinity engineering to typically intractable membrane proteins such as GPCRs.
Collapse
Key Words
- CDR, complementarity determining region
- FLIPR, Fluorescent Imaging Plate Reader
- FMAT, fluorometric microvolume assay technology
- FPR, formyl peptide receptor
- Fv, variable domain
- G-protein coupled receptor
- GPCR, G-protein coupled receptor
- IgG, immunoglobulin G
- MPL, magnetic proteoliposome
- RIMMS, repetitive immunization at multiple sites
- VH, variable heavy
- VL, variable light
- affinity maturation
- antibody crystal structure
- antibody engineering
- formyl peptide receptor-1
- homology modeling
- long CDR
- phage display
- scFv, single chain Fv fragment
Collapse
|
19
|
Badia J, Kittikorn T, Strömberg E, Santonja-Blasco L, Martínez-Felipe A, Ribes-Greus A, Ek M, Karlsson S. Water absorption and hydrothermal performance of PHBV/sisal biocomposites. Polym Degrad Stab 2014. [DOI: 10.1016/j.polymdegradstab.2014.04.012] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
20
|
Bodin C, Mauritzson F, Horsefield R, Aagaard A, Guo H, Öster L, Wissler L, Ek M. Solutions for the storage and handling of SPINE standard pucks. J Synchrotron Radiat 2012; 19:288-289. [PMID: 22338692 DOI: 10.1107/s0909049511054689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2011] [Accepted: 12/19/2011] [Indexed: 05/31/2023]
Abstract
Currently there is no rack system for the long-term storage of SPINE pucks in spite of their commercial availability and heavy usage at the ESRF. The only way to store pucks is in transport dewar canisters which presents a number of limitations and drawbacks. Here a simple affordable rack for storing SPINE pucks is described, which we believe is accessible to not only synchrotrons but also both academic and industrial research laboratories.
Collapse
Affiliation(s)
- Cristian Bodin
- Discovery Sciences, AstraZeneca R&D Mölndal, SE-43183 Mölndal, Sweden
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Hallermalm K, Johansson S, Bråve A, Ek M, Engström G, Boberg A, Gudmundsdotter L, Blomberg P, Mellstedt H, Stout R, Liu MA, Wahren B. Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer. Scand J Immunol 2007; 66:43-51. [PMID: 17587345 DOI: 10.1111/j.1365-3083.2007.01945.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
In preparation for a clinical trial in patients diagnosed with colorectal cancer, a vaccination strategy targeting the carcinoembryonic antigen (CEA) was evaluated in mice using a GMP-produced plasmid DNA vaccine, CEA66, encoding a truncated form of the tumour-associated antigen, CEA. The GMP-produced CEA DNA vaccine was also evaluated for toxicity. Repeated intradermal administration of the GMP-produced vaccine using a novel needle-free jet injection device (Biojector) induced robust CD4 and CD8 T-cell responses in mice, and did not result in any vaccine-related toxicity. In a heterologous DNA prime/protein boost setting, cellular immune responses were of higher magnitude in animals primed with CEA66 DNA than in animals receiving repeated doses of recombinant CEA protein. These responses were further enhanced if recombinant murine granulocyte-macrophage colony-stimulating factor was given as an adjuvant prior to vaccination. In contrast to repeated administration of recombinant CEA protein as a single modality vaccine, the heterologous CEA66 DNA prime/rCEA boost vaccination strategy resulted in a qualitatively broader immune response, and supports clinical testing of this vaccination regimen in humans.
Collapse
Affiliation(s)
- K Hallermalm
- Department of Microbiology and Tumor and Cell Biology, Karolinska Institutet & Swedish Institute for Infectious Disease ControlCenter for Molecular Medicine, Karolinska InstitutetVecura, Cell & Gene Therapy Center, Karolinska SjukhusetCancer Center Karolinska, Karolinska Sjukhuset, Stockholm, SwedenBioject Medical Technologies Inc., Tualatin, OR, USAProTherImmune, Lafayette, CA, USA
| | - S Johansson
- Department of Microbiology and Tumor and Cell Biology, Karolinska Institutet & Swedish Institute for Infectious Disease ControlCenter for Molecular Medicine, Karolinska InstitutetVecura, Cell & Gene Therapy Center, Karolinska SjukhusetCancer Center Karolinska, Karolinska Sjukhuset, Stockholm, SwedenBioject Medical Technologies Inc., Tualatin, OR, USAProTherImmune, Lafayette, CA, USA
| | - A Bråve
- Department of Microbiology and Tumor and Cell Biology, Karolinska Institutet & Swedish Institute for Infectious Disease ControlCenter for Molecular Medicine, Karolinska InstitutetVecura, Cell & Gene Therapy Center, Karolinska SjukhusetCancer Center Karolinska, Karolinska Sjukhuset, Stockholm, SwedenBioject Medical Technologies Inc., Tualatin, OR, USAProTherImmune, Lafayette, CA, USA
| | - M Ek
- Department of Microbiology and Tumor and Cell Biology, Karolinska Institutet & Swedish Institute for Infectious Disease ControlCenter for Molecular Medicine, Karolinska InstitutetVecura, Cell & Gene Therapy Center, Karolinska SjukhusetCancer Center Karolinska, Karolinska Sjukhuset, Stockholm, SwedenBioject Medical Technologies Inc., Tualatin, OR, USAProTherImmune, Lafayette, CA, USA
| | - G Engström
- Department of Microbiology and Tumor and Cell Biology, Karolinska Institutet & Swedish Institute for Infectious Disease ControlCenter for Molecular Medicine, Karolinska InstitutetVecura, Cell & Gene Therapy Center, Karolinska SjukhusetCancer Center Karolinska, Karolinska Sjukhuset, Stockholm, SwedenBioject Medical Technologies Inc., Tualatin, OR, USAProTherImmune, Lafayette, CA, USA
| | - A Boberg
- Department of Microbiology and Tumor and Cell Biology, Karolinska Institutet & Swedish Institute for Infectious Disease ControlCenter for Molecular Medicine, Karolinska InstitutetVecura, Cell & Gene Therapy Center, Karolinska SjukhusetCancer Center Karolinska, Karolinska Sjukhuset, Stockholm, SwedenBioject Medical Technologies Inc., Tualatin, OR, USAProTherImmune, Lafayette, CA, USA
| | - L Gudmundsdotter
- Department of Microbiology and Tumor and Cell Biology, Karolinska Institutet & Swedish Institute for Infectious Disease ControlCenter for Molecular Medicine, Karolinska InstitutetVecura, Cell & Gene Therapy Center, Karolinska SjukhusetCancer Center Karolinska, Karolinska Sjukhuset, Stockholm, SwedenBioject Medical Technologies Inc., Tualatin, OR, USAProTherImmune, Lafayette, CA, USA
| | - P Blomberg
- Department of Microbiology and Tumor and Cell Biology, Karolinska Institutet & Swedish Institute for Infectious Disease ControlCenter for Molecular Medicine, Karolinska InstitutetVecura, Cell & Gene Therapy Center, Karolinska SjukhusetCancer Center Karolinska, Karolinska Sjukhuset, Stockholm, SwedenBioject Medical Technologies Inc., Tualatin, OR, USAProTherImmune, Lafayette, CA, USA
| | - H Mellstedt
- Department of Microbiology and Tumor and Cell Biology, Karolinska Institutet & Swedish Institute for Infectious Disease ControlCenter for Molecular Medicine, Karolinska InstitutetVecura, Cell & Gene Therapy Center, Karolinska SjukhusetCancer Center Karolinska, Karolinska Sjukhuset, Stockholm, SwedenBioject Medical Technologies Inc., Tualatin, OR, USAProTherImmune, Lafayette, CA, USA
| | - R Stout
- Department of Microbiology and Tumor and Cell Biology, Karolinska Institutet & Swedish Institute for Infectious Disease ControlCenter for Molecular Medicine, Karolinska InstitutetVecura, Cell & Gene Therapy Center, Karolinska SjukhusetCancer Center Karolinska, Karolinska Sjukhuset, Stockholm, SwedenBioject Medical Technologies Inc., Tualatin, OR, USAProTherImmune, Lafayette, CA, USA
| | - M A Liu
- Department of Microbiology and Tumor and Cell Biology, Karolinska Institutet & Swedish Institute for Infectious Disease ControlCenter for Molecular Medicine, Karolinska InstitutetVecura, Cell & Gene Therapy Center, Karolinska SjukhusetCancer Center Karolinska, Karolinska Sjukhuset, Stockholm, SwedenBioject Medical Technologies Inc., Tualatin, OR, USAProTherImmune, Lafayette, CA, USA
| | - B Wahren
- Department of Microbiology and Tumor and Cell Biology, Karolinska Institutet & Swedish Institute for Infectious Disease ControlCenter for Molecular Medicine, Karolinska InstitutetVecura, Cell & Gene Therapy Center, Karolinska SjukhusetCancer Center Karolinska, Karolinska Sjukhuset, Stockholm, SwedenBioject Medical Technologies Inc., Tualatin, OR, USAProTherImmune, Lafayette, CA, USA
| |
Collapse
|
22
|
Popovic K, Brauner S, Ek M, Wahren-Herlenius M, Nyberg F. Fine specificity of the Ro/SSA autoantibody response in relation to serological and clinical findings in 96 patients with self-reported cutaneous symptoms induced by the sun. Lupus 2007; 16:10-7. [PMID: 17283579 DOI: 10.1177/0961203306073135] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Anti-Ro/SSA assays assist the clinician in distinguishing autoimmune diseases such as Sjögrenś syndrome (SS), systemic lupus erythematosus (SLE) and subacute cutaneous lupus erythematosus (SCLE). The objective of the study was to investigate the fine specificity of the autoantibodies in relation to clinical presentation as well as environmental and endogenous factors such as photosensitivity, smoking and immunoglobulin (Ig) levels in patients with Ro/SSA autoantibodies. Serum samples from 96 anti-Ro/SSA positive photosensitive patients were tested for autoantibody levels by enzyme-linked immunosorbent assay (ELISA) using purified recombinant Ro52 kd, Ro60 kd and La proteins as antigens. The highest levels of anti-Ro52 and anti-La were observed in patients with primary SS, and the lowest levels of anti-Ro52 in chronic cutaneous lupus erythematosus (CCLE). SCLE patients with systemic disease (SLE and/or SS) showed higher levels of anti-Ro52 than SCLE limited to the skin. A correlation between high serum levels of IgG and anti-Ro52 (P < 0.01) and between IgA and anti-Ro52 (P < 0.05) and anti-Ro60 (P < 0.05) was found. Polymorphic light eruption (PLE) was common in all diagnostic groups but did not correlate with autoantibody levels. Smoking was more common in lupus patients than in SS patients. Our findings thus propose different mechanisms for different clinical presentations of Ro/SSA positive patients. The testing of anti-Ro52 antibodies might serve as a prognostic tool in photosensitive cutaneous diseases.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Antinuclear/blood
- Antibodies, Antinuclear/immunology
- Antibody Specificity
- Antibody-Producing Cells/immunology
- Arthritis, Rheumatoid/diagnosis
- Arthritis, Rheumatoid/epidemiology
- Arthritis, Rheumatoid/immunology
- Autoantigens/immunology
- Biopsy
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Incidence
- Lupus Erythematosus, Cutaneous/diagnosis
- Lupus Erythematosus, Cutaneous/epidemiology
- Lupus Erythematosus, Cutaneous/etiology
- Lupus Erythematosus, Cutaneous/pathology
- Lupus Erythematosus, Systemic/diagnosis
- Lupus Erythematosus, Systemic/epidemiology
- Lupus Erythematosus, Systemic/immunology
- Male
- Middle Aged
- Photosensitivity Disorders/blood
- Photosensitivity Disorders/etiology
- Photosensitivity Disorders/immunology
- Prevalence
- Ribonucleoproteins/immunology
- Sjogren's Syndrome/diagnosis
- Sjogren's Syndrome/epidemiology
- Sjogren's Syndrome/immunology
- Skin/pathology
- Smoking/epidemiology
- Sunlight/adverse effects
- Sweden/epidemiology
- SS-B Antigen
Collapse
Affiliation(s)
- K Popovic
- Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Department of Dermatology, Stockholm, Sweden.
| | | | | | | | | |
Collapse
|
23
|
Ek M, Bergström R, Bjurhem JE, Björlenius B, Hellström D. Concentration of nutrients from urine and reject water from anaerobically digested sludge. Water Sci Technol 2006; 54:437-44. [PMID: 17302349 DOI: 10.2166/wst.2006.924] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
Experiments with concentration of nutrients from source separated urine and reject water from digestion of sludge in sewage treatment plants (STP) have been performed in laboratory and pilot scale. The methods tested were membrane filtration with reverse osmosis (RO), evaporation, and precipitation of phosphorus and distillation of ammonia. In membrane filtration, pre-filtration with particle separation at 5-10 microm was enough to avoid clogging of the membranes. Separation of phosphorus (P), potassium (K) and sulphur (S) was almost 100%, while separation of nitrogen (N) was dependent on pH. The capacity of flux increased with temperature and pressure. In evaporation, all P, K and S were still in the concentrate, while pH had to be decreased to 4.5 to avoid significant loss of N. In precipitation and distillation, about 90% of P could be recovered from urine as magnesium ammonium phosphate (MAP) just by adding MgO. For the reject water pH was first increased by aeration to remove CO2. Ammonium can be distilled from the water phase after precipitation of MAP, without further increase of pH. At least 80-90% of N can be distilled in 5-10% of the total volume. The article also discusses the quality of different products, cost of separation, and energy and chemical demand.
Collapse
Affiliation(s)
- M Ek
- IVL Swedish Environmental Research Institute, Box 21060, SE-100 31 Stockholm, Sweden.
| | | | | | | | | |
Collapse
|
24
|
Ek M, Eklund M, Von Post R, Dayteg C, Henriksson T, Weibull P, Ceplitis A, Isaac P, Tuvesson S. Microsatellite markers for powdery mildew resistance in pea (Pisum sativum L.). Hereditas 2005; 142:86-91. [PMID: 16970617 DOI: 10.1111/j.1601-5223.2005.01906.x] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Powdery mildew is a common disease of field pea, Pisum sativum L., and is caused by the ascomycete fungus Erysiphe pisi. It can cause severe damage in areas where pea is cultivated. Today breeders want to develop new pea lines that are resistant to the disease. To make the breeding process more efficient, it is desirable to find genetic markers for use in a marker-assisted selection (MAS) strategy. In this study, microsatellites (SSR) were used to find markers linked to powdery mildew resistance. The resistant pea cultivar '955180' and the susceptible pea cultivar 'Majoret' were crossed and F2 plants were screened with SSR markers, using bulked segregant analysis. A total of 315 SSR markers were screened out of which five showed linkage to the powdery mildew resistance gene. No single marker was considered optimal for inclusion in a MAS program. Instead, two of the markers can be used in combination, which would result in only 1.6% incorrectly identified plants. Thus SSR markers can be successfully used in marker-assisted selection for powdery mildew resistance breeding in pea.
Collapse
Affiliation(s)
- M Ek
- Department of Cell and Organism Biology (Genetics), Lund University, Lund, Sweden
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Engblom D, Ek M, Ericsson-Dahlstrand A, Blomqvist A. EP3 and EP4 receptor mRNA expression in peptidergic cell groups of the rat parabrachial nucleus. Neuroscience 2004; 126:989-99. [PMID: 15207332 DOI: 10.1016/j.neuroscience.2004.03.042] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/22/2004] [Indexed: 11/19/2022]
Abstract
This study examines the distribution of prostaglandin E2 receptors of subtype EP3 and EP4 among brain stem parabrachial neurons that were characterized with respect to their neuropeptide expression. By using a dual-labeling in situ hybridization method, we show that preprodynorphin mRNA expressing neurons in the dorsal and central lateral subnuclei express EP3 receptor mRNA. Such receptors are also expressed in preproenkephalin, calcitonin gene related peptide and preprotachykinin mRNA positive neurons in the external lateral subnucleus, whereas preprodynorphin mRNA expressing neurons in this subnucleus are EP receptor negative. In addition, EP3 receptor expression is seen among some enkephalinergic neurons in the Kölliker-Fuse nucleus. Neurons in the central part of the cholecystokininergic population in the regions of the superior lateral subnucleus express EP4 receptor mRNA, whereas those located more peripherally express EP3 receptors. Taken together with previous findings showing that discrete peptidergic cell groups mediate nociceptive and/or visceral afferent information to distinct brain stem and forebrain regions, the present results suggest that the processing of this information in the parabrachial nucleus is influenced by prostaglandin E2. Recent work has shown that prostaglandin E2 is released into the brain following peripheral immune challenge; hence, the parabrachial nucleus may be a region where humoral signaling of peripheral inflammatory events may interact with neuronal signaling elicited by the same peripheral processes.
Collapse
Affiliation(s)
- D Engblom
- Department of Cell Biology, Faculty of Health Sciences, University of Linköping, S-582 25, Linköping, Sweden.
| | | | | | | |
Collapse
|
26
|
Engblom D, Ek M, Ericsson-Dahlstrand A, Blomqvist A. Activation of prostanoid EP(3) and EP(4) receptor mRNA-expressing neurons in the rat parabrachial nucleus by intravenous injection of bacterial wall lipopolysaccharide. J Comp Neurol 2001; 440:378-86. [PMID: 11745629 DOI: 10.1002/cne.1391] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Systemic inflammation activates central autonomic circuits, such as neurons in the pontine parabrachial nucleus. This activation may be the result of afferent signaling through the vagus nerve, but it may also depend on central prostaglandin-mediated mechanisms. Recently, we have shown that neurons in the parts of the parabrachial nucleus that are activated by immune challenge express prostaglandin receptors of the EP(3) and EP(4) subtypes, but it remains to be determined if the prostaglandin receptor-expressing neurons are identical to those that respond to immune stimuli. In the present study, bacterial wall lipopolysaccharide was injected intravenously in adult male rats and the expression of c-fos mRNA and of EP(3) and EP(4) receptor mRNA was examined with complementary RNA probes labeled with digoxigenin and radioisotopes, respectively. Large numbers of neurons in the external lateral parabrachial subnucleus, a major target of vagal-solitary tract efferents, expressed c-fos mRNA. Quantitative analysis showed that about 60% (range 40%-79%) of these neurons also expressed EP(3) receptor mRNA. Conversely, slightly more than 50% (range 48%-63%) of the EP(3) receptor-expressing neurons in the same subnucleus coexpressed c-fos mRNA. In contrast, few EP(4) receptor-expressing neurons were c-fos positive, with the exception of a small population located in the superior lateral and dorsal lateral subnuclei. These findings show that immune challenge activates central autonomic neurons that could be the target of centrally produced prostaglandin E(2), suggesting that synaptic signaling and paracrine mechanisms may interact on these neurons.
Collapse
Affiliation(s)
- D Engblom
- Department of Cell Biology, Faculty of Health Sciences, University of Linköping, S-581 85 Linköping, Sweden
| | | | | | | |
Collapse
|
27
|
Affiliation(s)
- M Ek
- Department of Medicine, Unit of Rheumatology, The Karolinska Institute, Stockholm 17177, Sweden
| | | | | | | | | | | |
Collapse
|
28
|
Ek M, Arias C, Sawchenko P, Ericsson-Dahlstrand A. Distribution of the EP3 prostaglandin E(2) receptor subtype in the rat brain: relationship to sites of interleukin-1-induced cellular responsiveness. J Comp Neurol 2000; 428:5-20. [PMID: 11058221 DOI: 10.1002/1096-9861(20001204)428:1<5::aid-cne2>3.0.co;2-m] [Citation(s) in RCA: 142] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The activation of neurosecretory neurons that express corticotropin-releasing hormone (CRH) in response to increased circulating levels of interleukin-1beta (IL-1beta) depends on prostaglandin E(2) (PGE(2)) acting locally within the brain parenchyma. To identify potential central targets for PGE(2) relevant to pituitary-adrenal control, the distribution of mRNA encoding the PGE(2) receptor subtype EP3 (EP3R) was analyzed in rat brain. Hybridization histochemistry revealed prominent labeling of cells in discrete portions of the olfactory system, iso- and hippocampal cortices, and subcortical telencephalic structures in the septal region and amygdala. Labeling over the midline, intralaminar, and anterior thalamic groups was particularly prominent. EP3R expression was enriched in the median preoptic nucleus and adjoining aspects of the medial preoptic area (MPO) implicated in thermoregulatory/febrile responses and sleep induction. EP3R-expressing cells were also prominent in brainstem cell groups involved in nociceptive information processing/modulation (periaqueductal gray, locus coeruleus (LC), parabrachial nucleus (PB), caudal raphé nuclei), arousal and wakefulness (LC, midbrain raphé and tuberomammillary nuclei); and in conveying interoceptive input, including systemic IL-1 signals, to the endocrine hypothalamus (nucleus of the solitary tract (NTS) and rostral ventrolateral medulla [VLM]). Combined hybridization histochemical detection of EP3R mRNA with immunolocalization of IL-1beta-induced Fos protein expression identified cytokine-sensitive, EP3R-positive cells in the medial NTS, rostral VLM, and, to a lesser extent, aspects of the MPO. These findings are consistent with the view that increased circulating IL-1 may stimulate central neural mechanisms, including hypothalamic CRH neurons, through an EP3R-dependent mechanism involving PGE(2)-mediated activation of cells in the caudal medulla and/or preoptic region.
Collapse
Affiliation(s)
- M Ek
- Department of Medicine, Unit of Rheumatology, The Karolinska Institute, S-171 76, Stockholm, Sweden.
| | | | | | | |
Collapse
|
29
|
Engblom D, Ek M, Hallbeck M, Ericsson-Dahlstrand A, Blomqvist A. Distribution of prostaglandin EP(3) and EP(4) receptor mRNA in the rat parabrachial nucleus. Neurosci Lett 2000; 281:163-6. [PMID: 10704768 DOI: 10.1016/s0304-3940(00)00852-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
By using in situ hybridization, the distribution of mRNA for the PGE(2) receptors EP(3) and EP(4) was examined in the rat parabrachial nucleus (PB), a major brain stem relay for autonomic and nociceptive processing. EP(3) receptor mRNA was present in most subnuclei, with the densest labeling in the external lateral, dorsal lateral, superior lateral, central lateral and Kölliker-Fuse nuclei. EP(4) receptor mRNA expressing cells had a more restricted distribution, largely being confined to the superior lateral and adjacent parts of the dorsal and central lateral nuclei in a pattern complementary to that for EP(3) receptor mRNA. These findings suggest that EP(3) and EP(4) receptors in PB have distinct functional roles that include nociceptive processing, blood pressure regulation and feeding behavior.
Collapse
Affiliation(s)
- D Engblom
- Department of Cell Biology, Faculty of Health Sciences, University of Linköping, S-581 85, Linköping, Sweden
| | | | | | | | | |
Collapse
|
30
|
Ek M, Kurosawa M, Lundeberg T, Ericsson A. Activation of vagal afferents after intravenous injection of interleukin-1beta: role of endogenous prostaglandins. J Neurosci 1998; 18:9471-9. [PMID: 9801384 PMCID: PMC6792875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023] Open
Abstract
Intravenous administration of interleukin-1 (IL-1) activates central autonomic neuronal circuitries originating in the nucleus of the solitary tract (NTS). The mechanism(s) by which blood-borne IL-1 regulates brain functions, whether by operating across the blood-brain barrier and/or by activating peripheral sensory afferents, remains to be characterized. It has been proposed that vagal afferents originating in the periphery may monitor circulating IL-1 levels, because neurons within the NTS are primary recipients of sensory information from the vagus nerve and also exhibit exquisite sensitivity to blood-borne IL-1. In this study, we present evidence that viscerosensory afferents of the vagus nerve respond to intravenously administered IL-1beta. Specific labeling for mRNAs encoding the type 1 IL-1 receptor and the EP3 subtype of the prostaglandin E2 receptor was detected in situ over neuronal cell bodies in the rat nodose ganglion. Moreover, intravenously applied IL-1 increased the number of sensory neurons in the nodose ganglion that express the cellular activation marker c-Fos, which was matched by an increase in discharge activity of vagal afferents arising from gastric compartments. This response to IL-1 administration was attenuated in animals pretreated with the cyclooxygenase inhibitor indomethacin, suggesting partial mediation by prostaglandins. In conclusion, these results demonstrate that somata and/or fibers of sensory neurons of the vagus nerve express receptors to IL-1 and prostaglandin E2 and that circulating IL-1 stimulates vagal sensory activity via both prostaglandin-dependent and -independent mechanisms.
Collapse
Affiliation(s)
- M Ek
- Department of Medicine, Unit of Rheumatology, The Karolinska Institute, Stockholm, Sweden
| | | | | | | |
Collapse
|
31
|
Adelroth P, Ek M, Brzezinski P. Factors determining electron-transfer rates in cytochrome c oxidase: investigation of the oxygen reaction in the R. sphaeroides enzyme. Biochim Biophys Acta 1998; 1367:107-17. [PMID: 9784618 DOI: 10.1016/s0005-2728(98)00142-x] [Citation(s) in RCA: 77] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
We have investigated the kinetics of the single-turnover reaction of fully reduced solubilised cytochrome c oxidase (cytochrome aa3) from Rhodobacter sphaeroides with dioxygen using the flow-flash methodology and compared the results to those obtained with the well-characterised bovine mitochondrial enzyme. The overall reaction sequence was the same in the two enzymes, but the extents and rates of the electron-transfer reactions differed, implying differences in redox potentials, and/or interaction energies between electrons and protons during oxygen reduction. As with the bovine enzyme, the R. sphaeroides enzyme displayed two major kinetic phases of proton uptake with rate constants of approximately 5000 s-1 and approximately 500 s-1 at pH 7.9, concomitant with the peroxy to oxoferryl and oxoferryl to oxidised states. The net number of protons taken up in the R. sphaeroides enzyme was about approximately 1.9, which implies that upon reduction, the enzyme has to pick up approximately 2.1 H+ from the medium. On the basis of the comparison of electron-transfer reactions in the two enzymes, we conclude that the transfer rate of the fourth electron to the binuclear centre is not only determined by the electron-transfer rate from haem a to the binuclear centre, but also by the electron equilibrium between CuA and haem a. In addition, in contrast to the bovine enzyme, where the electron- and proton-transfer rates during oxidation of the fully reduced enzyme by O2 are all faster than the overall turnover rate, in the R. sphaeroides enzyme, the slowest kinetic phase was rate limiting for the overall turnover. Moreover, the comparison of the reactions in the two systems shows that in the R. sphaeroides enzyme, the electrons are more evenly distributed among the redox centres during oxygen reduction. This enables investigations of effects also of minor perturbations on, e.g., the electron-transfer characteristics in mutant enzymes, for which this study forms the basis.
Collapse
Affiliation(s)
- P Adelroth
- Department of Biochemistry and Biophysics, Göteborg University, P.O. Box 462, SE-405 30 Göteborg, Sweden
| | | | | |
Collapse
|
32
|
Grice J, Ek M, Greer B, Koh WJ, Muntz HG, Cain J, Tamimi H, Stelzer K, Figge D, Goff BA. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol 1998; 69:69-73. [PMID: 9571001 DOI: 10.1006/gyno.1998.4956] [Citation(s) in RCA: 122] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVE Earlier studies have demonstrated that the uterine papillary serous carcinoma (UPSC) variant of endometrial carcinoma has a high recurrence rate, even when disease is apparently confined to the uterus. The current study evaluated survival in patients with surgically staged UPSC. METHODS Patients with UPSC were identified from surgical pathology files and charts were retrospectively reviewed. Only patients who had undergone a TAH-BSO, lymph node dissection, and peritoneal cytology were included. RESULTS The FIGO stages of the 36 patients were 12 Stage I (4 IA, 4 IB, 4 IC), 2 Stage IIB, 13 Stage III (5 IIIA, 8 IIIC), and 9 Stage IV. Of the 14 Stage I/II patients, 6 did not receive adjuvant therapy, 5 received whole pelvic radiation (WPXRT), and 3 received whole abdominal radiation therapy (WART); after a median follow-up interval of 50 months only 2 (14%) of these Stage I/II patients have developed a recurrence. Both of the recurrences were in Stage IC patients who received radiation; 1 recurred in the radiation field. Of the 5 Stage IIIA patients, 3 patients declined therapy and 2 were treated with WART; 3 patients, including the 2 who received radiation therapy, are alive without disease. Of the 8 Stage IIIC patients, 2 declined postoperative therapy, 2 received WART, and 4 received WPXRT with an extended field to include paraaortic nodes. Four of the 6 Stage IIIC patients treated with curative intent are without evidence of disease and 1 died of unrelated causes after a median follow-up interval of 48 months. Both of the Stage IIIC patients who declined treatment recurred. Of the 9 patients with Stage IV disease, 8 have died of disease. CONCLUSION Women with UPSC have a good prognosis when surgical staging confirms that disease is confined to the uterus (Stage I/II). Surgical findings can also be used to tailor adjuvant radiation treatments. Further study is required to define the optimal treatment for women with metastatic UPSC.
Collapse
Affiliation(s)
- J Grice
- Department of Obstetrics and Gynecology, Seattle, Washington 98195, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Lichtenwalner A, Patton D, Emerson C, Anderson D, Ek M. Ovarian teratoma in a pigtailed macaque (Macaca nemestrina). Contemp Top Lab Anim Sci 1997; 36:86-8. [PMID: 16426029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Affiliation(s)
- A Lichtenwalner
- Department of Medicine, Division of Allergy and Infectious Disease, University of Washington, Seattle 98195, USA
| | | | | | | | | |
Collapse
|
34
|
Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, Nikrui N, Tamimi HK, Cain JM, Greer BE, Fuller AF. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60:412-7. [PMID: 8774649 DOI: 10.1006/gyno.1996.0065] [Citation(s) in RCA: 242] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Between 1982 and 1992, 24 women with Stage III clear cell ovarian cancer were identified from the tumor registry. Thirty-four women with Stage III papillary serous tumors treated between 1987 and 1989 were used as a comparison. All patients underwent cytoreductive surgery followed by conventional platinum-based chemotherapy. In the women with clear cell histology, nine (37.5%) had endometriosis in the surgical specimen compared with one (3%) in the papillary serous group (P = 0.002). Ten women (42%) with clear cell histology experienced a thromboembolic event during the course of treatment, compared to six (18%) in the papillary serous group (P = 0.05). In the group with clear cell histology, overall, 70% of women had progressive disease. Fifty-two percent experienced clinical progression while receiving platinum-based chemotherapy. In addition, four patients were found to have progressive disease at second-look laparotomy. Only two patients had a pathologic complete response. In the group with papillary serous histology, 29% overall had progressive disease while on chemotherapy (P = 0.005). The median survival for the women with clear cell histology was 12 months compared to 22 months for those with papillary serous (P = 0.02). For women with clear cell histology, univariate analysis was used to evaluate prognostic factors. Age less than 50 was a poor prognostic factor (P = 0.045). The presence of endometriosis, thromboembolic event, or optimal cytoreduction were not prognostic factors (P = 0.67, P = 0.34, P = 0.39). Patients with advanced clear cell ovarian cancer have a poor response to conventional platinum-based chemotherapy and overall prognosis is poor.
Collapse
Affiliation(s)
- B A Goff
- Vincent Memorial Gynecologic Oncology Division, Harvard Medical School, Boston, Massachusetts 02114, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Swisher EM, Gown AM, Skelly M, Ek M, Tamimi HK, Cain JM, Greer BE, Muntz HG, Goff BA. The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. Gynecol Oncol 1996; 60:81-8. [PMID: 8557233 DOI: 10.1006/gyno.1996.0015] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Uterine malignant mixed mesodermal tumors (MMMT) are highly malignant tumors containing both malignant glands and stroma, while adenosarcomas (AS) are less aggressive tumors composed of malignant stroma and benign glands. Immunohistochemistry was used to grade overexpression of p53 protein, HER-2/neu protein, epidermal growth factor receptor (EGFR), and Ki-67 antigen in both the glands and stroma of tissue from 20 women with MMMT and 6 women with AS. EGFR was overexpressed in 2 AS and 9 MMMT, and was more commonly found in the sarcomatous component than the carcinomatous component in MMMT (P = 0.03). p53 was not found in any AS samples and was strongly present in 6 MMMT samples with a random distribution between the malignant components. HER-2/neu protein was not overexpressed in any AS or primary MMMT. Ki-67 antigen, a marker of cell proliferation, was found at higher levels in MMMT than AS samples (P = 0.03) and high Ki-67 antigen expression correlated with a decreased survival in patients with MMMT (P = 0.004). Independent characterization of oncogene proteins in the malignant components of these heterogeneous tumors may provide insight into the histogenesis and behavior of these malignancies.
Collapse
Affiliation(s)
- E M Swisher
- Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle 98195, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
Previous studies have shown that enzyme supplementation therapy with alglucerase for type 1 Gaucher's disease is effective at doses of 30-130 U/kg per month. Since both the clinical presentation and the response to therapy in Gaucher's disease are highly variable, individual dosing seems indicated. This notion, as well as the high costs of alglucerase and the unknown long-term side-effects, led us to investigate the efficacy of an individualised very low dose of alglucerase. Twenty-five adults with symptomatic type 1 Gaucher's disease (thirteen splenectomised) received alglucerase 1.15 U/kg three times a week (15 U/kg per month). Every 6 months, the dose was halved, maintained, or doubled, according to the response (based on haematological variables and liver and spleen volume). After 6 months of treatment, eighteen (72%) patients had a response (seventeen moderate, one good). After 12 months (in nineteen patients) and 18 months (in seven patients), all had sustained improvement. Severe splenomegaly resulted in slower haematological responses. Our results are similar to those obtained by others with higher-dose regimens and better than a low-dose regimen of 10U/kg every 2 weeks. We conclude that very low initial doses of alglucerase, when administered frequently, are effective and cost-saving in the treatment of type 1 Gaucher's disease.
Collapse
Affiliation(s)
- C E Hollak
- Department of Internal Medicine, Academic Medical Centre, Amsterdam, Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Baeckström D, Zhang K, Asker N, Rüetschi U, Ek M, Hansson GC. Expression of the leukocyte-associated sialoglycoprotein CD43 by a colon carcinoma cell line. J Biol Chem 1995; 270:13688-92. [PMID: 7775421 DOI: 10.1074/jbc.270.23.13688] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
The colon adenocarcinoma cell line COLO 205 secretes L-CanAg, a mucin-like glycoprotein carrying the carcinoma-associated sialyl-Lewis a carbohydrate epitope. In an attempt to identify its apoprotein, an NH2-terminal peptide sequence was obtained from purified L-CanAg. In all interpretable positions, this sequence showed 100% identity to the NH2-terminal of human CD43 (leukosialin, sialophorin), a plasma membrane-bound sialoglycoprotein hitherto only identified in leukocytes and other hematopoietic cells. An antiserum against deglycosylated L-CanAg and an anti-CD43 antiserum both immunoprecipitated a 61-kDa band, interpreted as the CD43 precursor, from COLO 205 cells as well as from the known CD43-expressing cell line HL-60. Results from immunoprecipitations following pulse-chase experiments and tunicamycin treatments were in agreement with earlier studies on the CD43 precursor. RNA blot analysis confirmed the expression of CD43 by the COLO 205 cell line, whereas three other colon carcinoma cell lines were negative. The glycosylation-dependent monoclonal antibody Leu-22, which recognizes leukocyte CD43, failed to bind L-CanAg, probably due to its much more extensive glycosylation. We conclude that L-CanAg is the secreted extracellular domain of a novel glycoform of CD43 and that CD43, if expressed in other carcinoma cells, may have escaped notice in studies relying on glycosylation-dependent monoclonal antibodies against leukocyte CD43.
Collapse
Affiliation(s)
- D Baeckström
- Department of Medical Biochemistry, University of Göteborg, Sweden
| | | | | | | | | | | |
Collapse
|
38
|
Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG, Cain JM, Tamimi HK, Figge DC, Greer BE. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994; 54:264-8. [PMID: 8088602 DOI: 10.1006/gyno.1994.1208] [Citation(s) in RCA: 318] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Uterine papillary serous carcinoma (UPSC) is a distinct histologic type of endometrial cancer which is associated with a high relapse rate and poor prognosis. Between 1983 and 1993, 50 patients with UPSC of the endometrium were surgically staged. Thirty-three patients had pure UPSC and 17 had UPSC admixed with other histologies. Extrauterine disease was found in 36 women (72%). Lymph node metastases were present in 36% of women without myometrial invasion, 50% with inner one-half invasion, and 40% with outer one-half invasion. Similarly, the presence of intraperitoneal disease or positive washings did not correlate with increasing myometrial invasion. Grade and histology (mixed vs pure) were also not predictive of extrauterine disease. Patients with lymphatic/vascular space invasion (LVSI) were more likely to have extrauterine disease (85%); however, even without LVSI the incidence of extrauterine disease was 58% (P = 0.05). Unlike endometrioid adenocarcinomas, grade and depth of myometrial invasion were not significant predictors for extrauterine disease. This study reinforces the need for complete surgical staging in all patients with UPSC regardless of depth of invasion.
Collapse
Affiliation(s)
- B A Goff
- Department of Obstetrics and Gynecology, University of Washington, Seattle 98195
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Ek M. [Interview]. Vardfacket 1991; 15:8-9. [PMID: 1814107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
40
|
Abstract
We studied the presence of human papillomavirus (HPV) DNA by in situ hybridization in 74 colposcopically defined subclinical vulvar lesions obtained from 51 patients (mean age 25 years, range 18-42 years) referred for atypical Papanicolaou smears to the Colposcopy Clinic. Serial sections of formalin-fixed, paraffin-embedded biopsy tissue were stained by routine hematoxylin and eosin stain or were separately hybridized with biotin-labeled probes of HPV types 6, 11, 16, and 18 at high stringency and with mixed HPV probes at low stringency. Histologic evidence of HPV infection (koilocytosis or dysplasia) was found in eight lesions. Overall, 10 lesions were positive by in situ hybridization with HPV DNA. Although certain colposcopic features were more strongly associated with HPV DNA than others were, we were unable to demonstrate any consistent correlation between HPV DNA positivity or specific HPV DNA types and colposcopic categories. There was little correlation between HPV DNA positivity and the histopathologic incidence of HPV infection and dysplasia. Three of the 10 hybridization-positive lesions were severely dysplastic as compared with 0 of 64 nonhybridizing lesions. In spite of this association between HPV DNA and dysplasia, HPV DNA hybridization added no additional clinically relevant information to the histopathologic findings. We emphasize the significance of careful colposcopic examination of the vulva with directed biopsies.
Collapse
Affiliation(s)
- R Cone
- Department of Laboratory Medicine, University of Washington, Seattle
| | | | | | | | | | | | | |
Collapse
|
41
|
Soules MR, McLachlan RI, Ek M, Dahl KD, Cohen NL, Bremner WJ. Luteal phase deficiency: characterization of reproductive hormones over the menstrual cycle. J Clin Endocrinol Metab 1989; 69:804-12. [PMID: 2506214 DOI: 10.1210/jcem-69-4-804] [Citation(s) in RCA: 55] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The recurrent deficiency of progesterone (P) secretion by the corpus luteum has been associated with infertility and habitual abortion and given the clinical diagnosis of luteal phase deficiency (LPD). There is evidence that both follicular and luteal phase abnormalities can result in LPD cycles. In this study we have examined reproductive hormone levels and preovulatory follicular size in women with LPD (n = 10). For the purposes of this study, LPD was determined by an endometrial biopsy in the studied cycle that was more than 2 days out of phase. These biopsies were performed in women with infertility or habitual abortion who exhibited an out of phase biopsy in a prior cycle. The control group consisted of 28 normal women. Daily serum levels of the following hormones were determined in each subject: LH and FSH [immuno- and bioactive (LH-immuno and LH-bio)], P, estradiol (E2), and inhibin. The LPD women exhibited significant decreases in integrated luteal phase levels of inhibin [10,615 +/- 898 vs. 13,560 +/- 662 (U/L).days; P less than 0.02] and E2 [5,015 +/- 275 vs. 6,435 +/- 393 (pmol/L).days (1366 vs. 1753 (pg/mL).days); P less than 0.05] in addition to the expected decrease in P [280 +/- 23 vs. 420 +/- 23 (nmol/L).days (88 vs. 132 (ng/mL).days); P less than 0.01]. On days 6-11 after the LH surge (day 0), there was a significant (P less than 0.05) decrease in mean LH-bio levels in LPD compared with those in normal women (146 +/- 26 vs. 212 +/- 24 micrograms/L). The midcycle LH surge was deficient in LPD when both LH-immuno [482 +/- 30 vs. 672 +/- 43 (micrograms/L).days; P less than 0.01] and LH-bio [1711 +/- 179 vs. 2248 +/- 226 (micrograms/L).days; P less than 0.05] levels were compared with normal values. When comparing the follicular phase in LPD with that in normal women, similar follicle size, peak and integrated E2 levels, and mean LH and FSH (immuno and bio) levels were found. The only follicular phase abnormality noted in this study was decreased mean levels of serum inhibin in the early and midfollicular phases (221 +/- 19 vs. 308 +/- 25 U/L; P less than 0.01). In this group of women with LPD, low levels of inhibin in the follicular phase were consistent with the concept of a defect in function of the preovulatory follicle, possibly as a result of previously described defects in gonadotropin secretion in this condition.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- M R Soules
- Department of Obstetrics, University of Washington, Seattle 98195
| | | | | | | | | | | |
Collapse
|
42
|
Tamimi HK, Ek M, Hesla J, Cain JM, Figge DC, Greer BE. Glassy cell carcinoma of the cervix redefined. Obstet Gynecol 1988; 71:837-41. [PMID: 3368169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Glassy cell carcinoma of the cervix has been classically regarded as a poorly differentiated adenosquamous carcinoma, infrequently diagnosed and associated with a poor outcome regardless of the modality of therapy. The histologic characteristics associated with this lesion are also frequently encountered among undifferentiated large-cell, nonkeratinizing cervical carcinomas. In a review of all undifferentiated large-cell carcinomas of the cervix encountered at the University Hospital in Seattle, Washington, over an eight-year period, 29 cases appeared to display the characteristic histologic criteria described as typical for glassy cell carcinoma. All cases were stage Ib lesions, and 28 were treated by radical hysterectomy. The mean age was ten years younger than that of the usual patient treated at this institution with stage I carcinoma. Fourteen of these patients (45%) have developed recurrent carcinoma, and in all but one, the interval to recurrence was less than eight months. Only two have survived after second-line salvage therapy. The current survival rate among the 29 women is 55%. These observations suggest that the poor prognosis ascribed to the classically defined glassy cell carcinoma also holds true for this extended group of large-cell, undifferentiated cervical cancers that display similar histologic features and pursue a similarly aggressive clinical course.
Collapse
Affiliation(s)
- H K Tamimi
- Department of Obstetrics and Gynecology, University of Washington, Seattle
| | | | | | | | | | | |
Collapse
|
43
|
Russell AH, Burt AR, Ek M, Russell KJ, Cain JM, Greer BE, Tamimi HK, Figge DC. Adjunctive hysterectomy following radiation therapy for bulky carcinoma of the uterine cervix: prognostic implications of tumor persistence. Gynecol Oncol 1987; 28:220-4. [PMID: 3666580 DOI: 10.1016/0090-8258(87)90217-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Twenty-five patients underwent adjunctive extrafascial hysterectomy 14-60 days following completion of external and intracavitary irradiation for bulky carcinoma of the uterine cervix. Review of the operative histopathology and correlation with subsequent patient outcomes suggests that morphologically persistent cancer is prognostically ominous and that cancer near the surgical margin is viable in the majority of instances.
Collapse
Affiliation(s)
- A H Russell
- Department of Radiation Oncology, University of Washington School of Medicine, Seattle 98195
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Greer B, O'Neill M, Ness R, Figge D, Ek M, Tamimi H, Russell T. Stage IB carcinoma of the cervix with occult positive nodes: Prognostic factors. Gynecol Oncol 1985. [DOI: 10.1016/0090-8258(85)90158-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
45
|
Chu J, Tamimi HK, Ek M, Figge DC. Stage I vulvar cancer: criteria for microinvasion. Obstet Gynecol 1982; 59:716-9. [PMID: 7078910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Thirty-eight women with stage I epidermoid carcinoma of the vulva were studied retrospectively in an attempt to define the criteria for conservative therapy in early invasive vulvar cancer. Among the 38 women, 23 met the 6 criteria established for early invasive carcinoma of the vulva. In those 23 women, there were no nodal metastases. Depth of stromal invasion correlated strongly with the degree of tumor differentiation and the presence of carcinoma in situ (CIS). Stromal invasion less than 3 mm and presence of CIS were predictive of no involvement of the lymph nodes or endothelial-like space.
Collapse
|